Antibody-based therapeutics generated with current technologies inherently exhibit product heterogeneity due to modifications occurring throughout production. Comprehensive characterization is therefore essential to ensure consistent, safe, and effective therapeutic proteins. The strategic application of advanced analytical techniques can enhance candidate selection and inform development decisions, ultimately increasing the likelihood of bringing safer and more effective therapies to market. ProtaGene provides an integrated suite of analytical platforms to characterize antibody-based therapeutics, offering detailed insights into structure, stability, and purity.